Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorambucil + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Chlorambucil + obinutuzumab is a combination therapy used primarily for the initial treatment of previously untreated chronic lymphocytic leukemia (CLL) in patients with comorbidities. Chlorambucil is an alkylating agent that interferes with DNA replication and transcription by cross-linking DNA, resulting in cytotoxicity towards rapidly dividing cells. Obinutuzumab is a humanized, glycoengineered type II anti-CD20 monoclonal antibody that targets the CD20 antigen on B-lymphocytes, inducing B-cell lysis via multiple mechanisms including direct cell death, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). The combination improves progression-free survival and overall response rate compared to chlorambucil alone, and is administered intravenously[1][3][5][6].
- Brand names
- Gazyva + Leukeran
- Other names
- obinutuzumab-chlorambucilO-ClbG-Clb
02
Targets
Beyond the preview
Go deeper on chlorambucil + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorambucil + obinutuzumab.